Sanofi SA (NYSE:SNY) shares hit a new 52-week high during trading on Friday . The company traded as high as $45.70 and last traded at $45.65, with a volume of 27147 shares traded. The stock had previously closed at $44.92.
A number of equities analysts recently commented on the company. Zacks Investment Research raised Sanofi from a “hold” rating to a “buy” rating and set a $47.00 price target for the company in a research note on Thursday, August 29th. UBS Group upgraded shares of Sanofi from a “neutral” rating to a “buy” rating in a research report on Wednesday, August 14th. Jefferies Financial Group restated a “buy” rating on shares of Sanofi in a research report on Thursday, August 29th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Sanofi in a research note on Tuesday, August 6th. Finally, TheStreet raised shares of Sanofi from a “c+” rating to a “b-” rating in a research note on Friday, June 21st. Six investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $49.67.
The company has a current ratio of 1.22, a quick ratio of 0.85 and a debt-to-equity ratio of 0.40. The company’s fifty day moving average is $42.81 and its 200-day moving average is $42.81. The firm has a market capitalization of $114.43 billion, a P/E ratio of 14.53, a P/E/G ratio of 2.41 and a beta of 0.67.
In related news, major shareholder Sanofi acquired 93,750 shares of the firm’s stock in a transaction on Monday, July 22nd. The shares were purchased at an average cost of $16.00 per share, for a total transaction of $1,500,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.00% of the company’s stock.
Large investors have recently modified their holdings of the business. Lazard Asset Management LLC lifted its stake in shares of Sanofi by 47,594.3% in the 1st quarter. Lazard Asset Management LLC now owns 2,384,716 shares of the company’s stock valued at $105,595,000 after purchasing an additional 2,379,716 shares during the last quarter. Point72 Asset Management L.P. grew its stake in shares of Sanofi by 221.3% during the 2nd quarter. Point72 Asset Management L.P. now owns 1,285,000 shares of the company’s stock valued at $55,602,000 after buying an additional 885,000 shares during the period. Morgan Stanley lifted its holdings in Sanofi by 34.1% in the 2nd quarter. Morgan Stanley now owns 3,145,435 shares of the company’s stock worth $136,104,000 after buying an additional 800,612 shares in the last quarter. Nuveen Asset Management LLC bought a new stake in shares of Sanofi during the 2nd quarter valued at about $29,037,000. Finally, Schafer Cullen Capital Management Inc lifted its stake in shares of Sanofi by 106.8% in the 2nd quarter. Schafer Cullen Capital Management Inc now owns 728,871 shares of the company’s stock worth $30,088,000 after acquiring an additional 376,410 shares during the period. Institutional investors and hedge funds own 7.04% of the company’s stock.
Sanofi Company Profile (NYSE:SNY)
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Recommended Story: Investing strategies using the yield curve
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.